Evidence map›Paper›PMID 39004770›Full record

ArticleActa neuropathologica communications2024

Correction: Tau seed amplification assay reveals relationship between seeding and pathological forms of tau in Alzheimer's disease brain.

Bryan Frey, David Holzinger, Keenan Taylor, Dagmar E Ehrnhoefer, Andreas Striebinger, Sandra Biesinger, Laura Gasparini, Michael J O'Neill, Florian Wegner, Stefan Barghorn and 2 more

Abstract readPublished Erratum
In one paragraph

Article in Acta neuropathologica communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Bryan FreyAbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061, Ludwigshafen, Germany. bryan.frey@abbvie.com.ORCID http://orcid.org/0000-0002-3665-0051
David HolzingerAbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061, Ludwigshafen, Germany.
Keenan TaylorAbbVie Bioresearch Center, Biotherapeutics and Genetic Medicine Technologies, Worcester, MA, USA.
Dagmar E EhrnhoeferAbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061, Ludwigshafen, Germany.
Andreas StriebingerAbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061, Ludwigshafen, Germany.
Sandra BiesingerAbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061, Ludwigshafen, Germany.
Laura GaspariniAbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061, Ludwigshafen, Germany.
Michael J O'NeillAbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061, Ludwigshafen, Germany.
Florian WegnerDepartment of Neurology, Hannover Medical School, Hanover, Germany.
Stefan BarghornAbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061, Ludwigshafen, Germany.
Günter U HöglingerDepartment of Neurology, Hannover Medical School, Hanover, Germany.
Roland G HeymAbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061, Ludwigshafen, Germany. roland.heym@abbvie.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39004770
PMCPMC11247772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.